Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 81 (TMEM81) is a type I transmembrane glycoprotein with a single-pass helical transmembrane domain, a large extracellular immunoglobulin (Ig)-like domain, and a short cytoplasmic tail[1][5]. Its gene is located at chromosome 1q32.1 and encodes a 255-amino-acid protein, highly conserved among vertebrates[1][3]. TMEM81 is ubiquitously expressed in humans with enhanced levels in cerebellum, testis, and spleen, and is present in spermatids of both mice and humans[1][3]. Structural studies identify TMEM81 as a close homolog of sperm fusion molecules (IZUMO1, SPACA6), suggesting a putative role in gamete membrane fusion or recognition[2][3][7]. Clinically, methylation changes or genetic variation in TMEM81 are associated with several diseases, including breast cancer, Meniere’s disease, mean platelet volume traits, and intermittent explosive disorder[1]. No drugs are currently known to target TMEM81, and its function and clinical utility remain incompletely characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 81 (TMEM81).